{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:23:26Z","timestamp":1794947006707,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cancers are immunologically heterogeneous.\u00a0A range of immunotherapies target abnormal tumor immunity via different mechanisms of actions (MOAs), particularly various tumor-infiltrate leukocytes (TILs). We modeled loss of function (LOF) in four common anti-PD-1 antibody-responsive syngeneic tumors, MC38, Hepa1-6, CT-26 and EMT-6, by systematical depleting a series of TIL lineages to explore the mechanisms of tumor immunity and treatment. CD8\n                    <jats:sup>+<\/jats:sup>\n                    -T-cells, CD4\n                    <jats:sup>+<\/jats:sup>\n                    -T-cells, T\n                    <jats:sub>reg<\/jats:sub>\n                    , NK cells and macrophages were individually depleted through either direct administration of anti-marker antibodies\/reagents or using DTR (diphtheria toxin receptor) knock-in mice, for some syngeneic tumors, where specific subsets were depleted following diphtheria toxin (DT) administration. These LOF experiments revealed distinctive intrinsic tumor immunity and thus different MOAs in their responses to anti-PD-1 antibody among different syngeneic tumors. Specifically, the intrinsic tumor immunity and the associated anti-PD-1 MOA were predominately driven by CD8\n                    <jats:sup>+<\/jats:sup>\n                    cytotoxic TILs (CTL) in all syngeneic tumors, excluding Hepa1-6 where CD4\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>eff<\/jats:sub>\n                    TILs played a key role. TIL-T\n                    <jats:sub>reg<\/jats:sub>\n                    also played a critical role in supporting tumor growth in all four syngeneic models as well as M\n                    <jats:sub>2<\/jats:sub>\n                    -macrophages. Pathway analysis using pharmacodynamic readouts of immuno-genomics and proteomics on MC38 and Hepa1-6 also revealed defined, but distinctive, immune pathways of activation and suppression between the two, closely associated with the efficacy and consistent with TIL-pharmacodynamic readouts. Understanding tumor immune-pathogenesis and treatment MOAs in the different syngeneic animal models, not only assists the selection of the right model for evaluating new immunotherapy of a given MOA, but also can potentially help to understand the potential disease mechanisms and strategize optimal immune-therapies in patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-07153-z","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T06:02:49Z","timestamp":1646028169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment"],"prefix":"10.1038","volume":"12","author":[{"given":"Ying","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binchen","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongli","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfa","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Muntel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Beeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Bruderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"7153_CR1","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2016.08.011","volume":"30","author":"H Tang","year":"2016","unstructured":"Tang, H. et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 30, 500. https:\/\/doi.org\/10.1016\/j.ccell.2016.08.011 (2016).","journal-title":"Cancer Cell"},{"key":"7153_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coi.2016.05.006","volume":"41","author":"JA Wargo","year":"2016","unstructured":"Wargo, J. A., Reddy, S. M., Reuben, A. & Sharma, P. Monitoring immune responses in the tumor microenvironment. Curr. Opin. Immunol. 41, 23\u201331. https:\/\/doi.org\/10.1016\/j.coi.2016.05.006 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"7153_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"7153_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172 (2015).","journal-title":"Science"},{"key":"7153_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.998538","volume":"4","author":"L Apetoh","year":"2015","unstructured":"Apetoh, L. et al. Consensus nomenclature for CD8+ T cell phenotypes in cancer. Oncoimmunology 4, e998538. https:\/\/doi.org\/10.1080\/2162402X.2014.998538 (2015).","journal-title":"Oncoimmunology"},{"key":"7153_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421. https:\/\/doi.org\/10.1038\/nature19330 (2016).","journal-title":"Nature"},{"key":"7153_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1126\/scitranslmed.3008918","volume":"6","author":"P Kvistborg","year":"2014","unstructured":"Kvistborg, P. et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl. Med. 6, 254. https:\/\/doi.org\/10.1126\/scitranslmed.3008918 (2014).","journal-title":"Sci. Transl. Med."},{"key":"7153_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.02.002","volume":"173","author":"QX Li","year":"2017","unstructured":"Li, Q. X., Feuer, G., Ouyang, X. & An, X. Experimental animal modeling for immuno-oncology. Pharmacol. Ther. 173, 34\u201346. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.002 (2017).","journal-title":"Pharmacol. Ther."},{"key":"7153_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"CP Day","year":"2015","unstructured":"Day, C. P., Merlino, G. & Van Dyke, T. Preclinical mouse cancer models: A maze of opportunities and challenges. Cell 163, 39\u201353. https:\/\/doi.org\/10.1016\/j.cell.2015.08.068 (2015).","journal-title":"Cell"},{"key":"7153_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nri3129","volume":"12","author":"G Dranoff","year":"2011","unstructured":"Dranoff, G. Experimental mouse tumour models: What can be learnt about human cancer immunology?. Nat. Rev. Immunol. 12, 61\u201366. https:\/\/doi.org\/10.1038\/nri3129 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"7153_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2353\/ajpath.2007.060929","volume":"170","author":"JE Talmadge","year":"2007","unstructured":"Talmadge, J. E., Singh, R. K., Fidler, I. J. & Raz, A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am. J. Pathol. 170, 793\u2013804. https:\/\/doi.org\/10.2353\/ajpath.2007.060929 (2007).","journal-title":"Am. J. Pathol."},{"key":"7153_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","volume":"5","author":"SI Mosely","year":"2017","unstructured":"Mosely, S. I. et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol. Res. 5, 29\u201341. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0114 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"7153_CR13","first-page":"2","volume":"2","author":"XO XiaoyuAn","year":"2018","unstructured":"XiaoyuAn, X. O., Hui, Z., Tingting, L., Demin, Z. & Qi-Xiang, L. Immunophenotyping of orthotopic homograft (syngeneic) of murine primary kpc pancreatic 2 ductal adenocarcinoma by flow cytometry. Jove 2, 2 (2018).","journal-title":"Jove"},{"key":"7153_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206223","volume":"13","author":"JW Yu","year":"2018","unstructured":"Yu, J. W. et al. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS ONE 13, e0206223. https:\/\/doi.org\/10.1371\/journal.pone.0206223 (2018).","journal-title":"PLoS ONE"},{"key":"7153_CR15","doi-asserted-by":"publisher","unstructured":"Chen, D. X. A. In vivo pharmacology models for cancer target research. Ju\u00a8 rgen Moll and Sebastian Carotta (eds.), Target Identification and Validation in Drug Discovery: Methods and Protocols, Methods in Molecular Biology, vol. 1953, https:\/\/doi.org\/10.1007\/978-1-4939-9145-7_12, \u00a9 Springer Science+Business Media, LLC, part of Springer Nature 2019 (2019).","DOI":"10.1007\/978-1-4939-9145-7_12"},{"key":"7153_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001983","volume":"3","author":"JF Curtin","year":"2008","unstructured":"Curtin, J. F. et al. Treg depletion inhibits efficacy of cancer immunotherapy: Implications for clinical trials. PLoS ONE 3, e1983. https:\/\/doi.org\/10.1371\/journal.pone.0001983 (2008).","journal-title":"PLoS ONE"},{"key":"7153_CR17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/90795","volume":"19","author":"M Saito","year":"2001","unstructured":"Saito, M. et al. Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat. Biotechnol. 19, 746\u2013750. https:\/\/doi.org\/10.1038\/90795 (2001).","journal-title":"Nat. Biotechnol."},{"key":"7153_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1084\/jem.194.6.823","volume":"194","author":"RP Sutmuller","year":"2001","unstructured":"Sutmuller, R. P. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823\u2013832. https:\/\/doi.org\/10.1084\/jem.194.6.823 (2001).","journal-title":"J. Exp. Med."},{"key":"7153_CR19","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00262-010-0855-8","volume":"59","author":"S Ostrand-Rosenberg","year":"2010","unstructured":"Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunotherapy CII 59, 1593\u20131600. https:\/\/doi.org\/10.1007\/s00262-010-0855-8 (2010).","journal-title":"Cancer Immunol. Immunotherapy CII"},{"key":"7153_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","volume":"128","author":"KH Parker","year":"2015","unstructured":"Parker, K. H., Beury, D. W. & Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: Critical cells driving immune suppression in the tumor microenvironment. Adv. Cancer Res. 128, 95\u2013139. https:\/\/doi.org\/10.1016\/bs.acr.2015.04.002 (2015).","journal-title":"Adv. Cancer Res."},{"key":"7153_CR21","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1158\/0008-5472.CAN-15-3245","volume":"76","author":"S Guo","year":"2016","unstructured":"Guo, S. et al. Molecular pathology of patient tumors, patient-derived xenografts, and cancer cell lines. Cancer Res. 76, 4619\u20134626. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-3245 (2016).","journal-title":"Cancer Res."},{"key":"7153_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7. https:\/\/doi.org\/10.1186\/1471-2105-14-7 (2013).","journal-title":"BMC Bioinform."},{"key":"7153_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0377-0427(87)90125-7","volume":"20","author":"PJ Rousseeuw","year":"1987","unstructured":"Rousseeuw, P. J. Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. J. Comput. Appl. Math. 20, 53\u201365. https:\/\/doi.org\/10.1016\/0377-0427(87)90125-7 (1987).","journal-title":"J. Comput. Appl. Math."},{"key":"7153_CR24","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560. https:\/\/doi.org\/10.1038\/s41586-019-1906-8 (2020).","journal-title":"Nature"},{"key":"7153_CR25","doi-asserted-by":"publisher","first-page":"E74","DOI":"10.1002\/ijc.27813","volume":"132","author":"M Yang","year":"2013","unstructured":"Yang, M. et al. Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naive Asian NSCLC patients. Int. J. Cancer 132, E74-84. https:\/\/doi.org\/10.1002\/ijc.27813 (2013).","journal-title":"Int. J. Cancer"},{"key":"7153_CR26","doi-asserted-by":"publisher","DOI":"10.3791\/57460","author":"X An","year":"2018","unstructured":"An, X. et al. Immunophenotyping of orthotopic homograft (syngeneic) of murine primary KPC pancreatic ductal adenocarcinoma by flow cytometry. J. Vis. Exp. JoVE https:\/\/doi.org\/10.3791\/57460 (2018).","journal-title":"J. Vis. Exp. JoVE"},{"key":"7153_CR27","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLOS Biol. 18, e3000410. https:\/\/doi.org\/10.1371\/journal.pbio.3000410 (2020).","journal-title":"PLOS Biol."},{"key":"7153_CR28","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1158\/0008-5472.CAN-16-0797","volume":"77","author":"AE Mahne","year":"2017","unstructured":"Mahne, A. E. et al. Dual roles for regulatory t-cell depletion and costimulatory signaling in agonistic GITR targeting for tumor immunotherapy. Can. Res. 77, 1108. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0797 (2017).","journal-title":"Can. Res."},{"key":"7153_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol."},{"key":"7153_CR30","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1093\/nar\/gku864","volume":"42","author":"JT Leek","year":"2014","unstructured":"Leek, J. T. svaseq: Removing batch effects and other unwanted noise from sequencing data. Nucleic Acids Res. 42, e161\u2013e161. https:\/\/doi.org\/10.1093\/nar\/gku864 (2014).","journal-title":"Nucleic Acids Res."},{"key":"7153_CR31","doi-asserted-by":"publisher","DOI":"10.1101\/060012","author":"G Korotkevich","year":"2019","unstructured":"Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. BioRxiv https:\/\/doi.org\/10.1101\/060012 (2019).","journal-title":"BioRxiv"},{"key":"7153_CR32","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102 (2005).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"7153_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004 (2015).","journal-title":"Cell Syst."},{"key":"7153_CR34","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1093\/bioinformatics\/btx378","volume":"33","author":"T Xu","year":"2017","unstructured":"Xu, T. et al. CancerSubtypes: An R\/Bioconductor package for molecular cancer subtype identification, validation and visualization. Bioinformatics 33, 3131\u20133133. https:\/\/doi.org\/10.1093\/bioinformatics\/btx378 (2017).","journal-title":"Bioinformatics"},{"key":"7153_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1023\/A:1023949509487","volume":"52","author":"S Monti","year":"2003","unstructured":"Monti, S., Tamayo, P., Mesirov, J. & Golub, T. Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. Mach. Learn. 52, 91\u2013118. https:\/\/doi.org\/10.1023\/A:1023949509487 (2003).","journal-title":"Mach. Learn."},{"key":"7153_CR36","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1074\/mcp.ra117.000189","volume":"17","author":"K Buczak","year":"2018","unstructured":"Buczak, K. et al. Spatial tissue proteomics quantifies inter- and intratumor heterogeneity in hepatocellular carcinoma (HCC). Mol. Cell. Proteom. MCP 17, 810\u2013825. https:\/\/doi.org\/10.1074\/mcp.ra117.000189 (2018).","journal-title":"Mol. Cell. Proteom. MCP"},{"key":"7153_CR37","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1038\/s41596-020-0356-y","volume":"15","author":"K Buczak","year":"2020","unstructured":"Buczak, K. et al. Spatially resolved analysis of FFPE tissue proteomes by quantitative mass spectrometry. Nat. Protoc. 15, 2956\u20132979. https:\/\/doi.org\/10.1038\/s41596-020-0356-y (2020).","journal-title":"Nat. Protoc."},{"key":"7153_CR38","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1074\/mcp.RA117.000314","volume":"16","author":"R Bruderer","year":"2017","unstructured":"Bruderer, R. et al. Optimization of experimental parameters in data-independent mass spectrometry significantly increases depth and reproducibility of results. Mol. Cell Proteom. 16, 2296\u20132309. https:\/\/doi.org\/10.1074\/mcp.RA117.000314 (2017).","journal-title":"Mol. Cell Proteom."},{"key":"7153_CR39","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1074\/mcp.m900317-mcp200","volume":"8","author":"L Reiter","year":"2009","unstructured":"Reiter, L. et al. Protein identification false discovery rates for very large proteomics data sets generated by tandem mass spectrometry. Mol. Cell. Proteom. MCP 8, 2405\u20132417. https:\/\/doi.org\/10.1074\/mcp.m900317-mcp200 (2009).","journal-title":"Mol. Cell. Proteom. MCP"},{"key":"7153_CR40","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1074\/mcp.m114.046995","volume":"14","author":"MM Savitski","year":"2015","unstructured":"Savitski, M. M., Wilhelm, M., Hahne, H., Kuster, B. & Bantscheff, M. A scalable approach for protein false discovery rate estimation in large proteomic data sets. Mol. Cell. Proteom. MCP 14, 2394\u20132404. https:\/\/doi.org\/10.1074\/mcp.m114.046995 (2015).","journal-title":"Mol. Cell. Proteom. MCP"},{"key":"7153_CR41","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1039\/c9mo00082h","volume":"15","author":"J Muntel","year":"2019","unstructured":"Muntel, J. et al. Surpassing 10 000 identified and quantified proteins in a single run by optimizing current LC-MS instrumentation and data analysis strategy. Mol. Omics 15, 348\u2013360. https:\/\/doi.org\/10.1039\/c9mo00082h (2019).","journal-title":"Mol. Omics"},{"key":"7153_CR42","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1074\/mcp.m114.044305","volume":"14","author":"R Bruderer","year":"2015","unstructured":"Bruderer, R. et al. Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues. Mol. Cell. Proteom. MCP 14, 1400\u20131410. https:\/\/doi.org\/10.1074\/mcp.m114.044305 (2015).","journal-title":"Mol. Cell. Proteom. MCP"},{"key":"7153_CR43","unstructured":"R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available online at\u00a0https:\/\/www.R-project.org\/."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07153-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07153-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07153-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:25:18Z","timestamp":1669314318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-07153-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7153"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-07153-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"assertion":[{"value":"31 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3278"}}